2 Biotech Stocks to Buy Hand Over Fist in February

As we step into February 2025, the biotechnology sector is buzzing with anticipation, as several companies await crucial FDA decisions that could significantly impact their future growth and revenue. Among these, two biotech stocks stand out as strong investment opportunities: Supernus Pharmaceuticals Inc. (SUPN) and Indivior PLC (INDV). Both companies have promising products in the pipeline, and their upcoming FDA decisions could unlock substantial value for investors.



Supernus Pharmaceuticals Inc. (SUPN)

Supernus Pharmaceuticals is awaiting an FDA decision on February 1, 2025, for its investigational apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations in Parkinson's disease. If approved, SPN-830 could provide a new treatment option for Parkinson's patients, potentially expanding Supernus' market share and driving growth. The Parkinson's disease market is large and growing, with an estimated 6.1 million people affected globally in 2019, presenting a significant opportunity for Supernus.



Supernus has had three previous attempts to gain FDA approval for SPN-830, with the FDA issuing Complete Response Letters in October 2022 and April 2024. However, the company's persistence and the positive data from these trials indicate the potential of this product. If approved, SPN-830 could provide a more convenient and effective treatment option for Parkinson's patients, potentially driving growth for Supernus.

Indivior PLC (INDV)

Indivior's Prior Approval Supplement for its SUBLOCADE product is under priority review by the FDA, with a decision due on February 7, 2025. SUBLOCADE is a monthly injectable formulation of buprenorphine for the treatment of moderate to severe opioid use disorder. The Prior Approval Supplement seeks to expand the injection sites and support rapid induction, which could increase the drug's accessibility and convenience for patients. If approved, these changes could lead to increased market penetration and revenue growth for Indivior.



The opioid use disorder market is significant, with an estimated 2.6 million people in the U.S. alone affected in 2019. An approval for the expanded label could help Indivior capture a larger share of this market, driving growth for the company. Additionally, Indivior's stock price has shown resilience, with a 0.41% increase on February 10, 2025, indicating potential for further growth.

In conclusion, both Supernus Pharmaceuticals Inc. (SUPN) and Indivior PLC (INDV) present compelling investment opportunities in February 2025. Their upcoming FDA decisions could unlock substantial value for investors, and their products address large and growing markets. While there are risks associated with these stocks, such as the uncertainty of FDA approval and market competition, the potential rewards make them attractive investments for those looking to capitalize on the biotechnology sector's growth. As always, investors should conduct thorough research and consider their risk tolerance before making any investment decisions.